Search results for "AEM"

showing 10 items of 1006 documents

Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a dec…

2022

Objectives: The aim of this study was to assess the incidence of being overweight and metabolic syndrome (MS) among people living with HIV (PHIV) in three different cross-sectional studies conducted over three different periods: 2005, 2011 and 2015. Methods: This was a multi-centre, nationwide study. Data were collected in three studies from the CISAI group - SIMOne, HIV-HY and STOPSHIV - and included a total of 3014 PHIV. Logistic regression [odds ratio (OR), 95% confidence interval (CI)] was used to account for age and gender difference among three groups when comparing MS prevalence and being overweight; potential confounders were accounted for by including them in the regression equatio…

AdultMaledyslipidaemiaantiretroviral therapyHIV InfectionsOverweightLogistic regressionBody Mass IndexCohort StudiesPrevalencemedicineoverweightHumansPharmacology (medical)Metabolic Syndromebusiness.industryHealth PolicyIncidence (epidemiology)Body WeightHIVweight gainOdds ratioMiddle Agedmedicine.diseaseConfidence intervalHIV; antiretroviral therapy; dyslipidaemia; metabolic syndrome; overweight; weight gainCross-Sectional StudiesInfectious Diseasesweight gain.Metabolic syndromemedicine.symptombusinessWeight gainDemographyCohort studyHIV Medicine
researchProduct

Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with …

2019

Background Conflicting data have been published as to the risk of cytomegalovirus (CMV) DNAemia and CMV disease in patients undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplantation cyclophosphamide. Methods We conducted a multicenter retrospective study including 118 patients subjected to unmanipulated haplo-HSCT to further clarify this issue. An historic cohort comprising 165 patients undergoing other transplant modalities (HLA-matched related, matched unrelated or mismatched) was built for comparison purposes. Plasma CMV DNA monitoring was performed using two highly sensitive real-time PCR assays. Results Overall, the cumulative incidence of…

AdultMaleendocrine systemmedicine.medical_specialtyAdolescentCyclophosphamidemedicine.medical_treatmentCongenital cytomegalovirus infectionCytomegalovirusHematopoietic stem cell transplantationYoung AdultInternal medicinemedicineHumansTransplantation HomologousCumulative incidenceCyclophosphamideAgedRetrospective StudiesTransplantationbusiness.industryIncidenceIncidence (epidemiology)Hematopoietic Stem Cell Transplantationvirus diseasesRetrospective cohort studyCmv dnaemiaMiddle AgedViral Loadmedicine.diseasesurgical procedures operativeInfectious DiseasesSpainCytomegalovirus InfectionsDNA ViralCohortFemalebusinessImmunosuppressive Agentsmedicine.drugTransplant Infectious Disease
researchProduct

Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered ce…

2011

Disappearance of normal bone marrow (BM) plasma cells (PC) predicts malignant transformation of monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM) into symptomatic multiple myeloma (MM). The homing, behavior and survival of normal PC, but also CD34 hematopoietic stem cells (HSC), B-cell precursors, and clonal PC largely depends on their interaction with stromal cell-derived factor-1 (SDF-1) expressing, potentially overlapping BM stromal cell niches. Here, we investigate the distribution, phenotypic characteristics and competitive migration capacity of these cell populations in patients with MGUS, SMM and MM vs healthy adults (HA) aged 60 years. Our result…

AdultMalemalignant transformationCancer ResearchPathologymedicine.medical_specialtyStromal cellPlasma CellsParaproteinemiasCD34Bone Marrow CellsEnzyme-Linked Immunosorbent AssayBiologyplasma cellsImmunophenotypingImmunophenotypingCell Movementhemic and lymphatic diseasesmedicineHumansProspective StudiesCells CulturedMultiple myelomaAgedAged 80 and overB-Lymphocytesmonoclonal gammopathiesbone marrow niche competitionHematologyMiddle AgedFlow CytometryHematopoietic Stem Cellsmedicine.diseaseClone CellsHaematopoiesisLeukemiamedicine.anatomical_structureOncologyCase-Control StudiesCancer researchFemaleBone marrowMultiple MyelomaMonoclonal gammopathy of undetermined significanceLeukemia
researchProduct

Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A

2018

Introduction: Personalised pharmacokinetics (PK) using Bayesian analysis with limited sampling is assumed to help to optimise prophylaxis in haemophilia A (HA) patients. Materials and methods: Our prospective, observational study analysed the influence of PK parameters on clinical variables (bleeding rates, joint status, adherence, and consumption) using myPKFiT (R) in a cohort of twenty-one severe and moderate HA patients on prophylaxis with recombinant FVIII (Advate (R)) in two periods of one year, the first before PK-based tailoring and the second after PK-guided prophylaxis. Intra-individual and inter-individual coefficients of variation (CV) of half-life (t(1/2)) were calculated. Resul…

AdultMalemedicine.medical_specialtyAdolescentHaemophilia AModerate haemophilia A030204 cardiovascular system & hematologyHemophilia ARecombinant factor viiiRecombinant factor VIIIYoung Adult03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicineHaemophilia AArthropathymedicineLimited samplingHumansPharmacokineticsProspective StudiesAgedFactor VIIIbusiness.industryBayes TheoremHematologyBayesian estimationMiddle Agedmedicine.diseasePK-guided prophylaxis030220 oncology & carcinogenesisCohortFemaleObservational studybusinessmyPKFiTThrombosis Research
researchProduct

Surface electrical stimulation of the quadriceps femoris in patients affected by haemophilia A.

2006

Eighteen sessions of surface electrical stimulation was applied to the quadriceps femoris of the left leg of ten male subjects affected by severe haemophilia A, while ten healthy subjects constituted the control group. The isometric strength, the electromyographic activity and the diameter of the rectus femoris were measured in both legs before and after a six-week treatment period. After the treatment, the people affected by haemophilia showed a gain in strength by 13.8% in the stimulated leg and by 17.1% in the non-stimulated one. No changes were detected in the electromyographic activity. On the contrary, the diameter of the rectus femoris of the stimulated leg increased in 24.34%, while…

AdultMalemedicine.medical_specialtyAdolescentHaemophilia AStimulationElectric Stimulation TherapyIsometric exerciseHaemophiliaHemophilia AQuadriceps MusclePhysical medicine and rehabilitationIsometric ContractionmedicineHumansIn patientGenetics (clinical)business.industryHealthy subjectsHematologyGeneral MedicineMiddle Agedmedicine.diseaseTreatment periodAnesthesiaCase-Control StudiesSevere haemophilia AbusinessHaemophilia : the official journal of the World Federation of Hemophilia
researchProduct

Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series

2020

BAY 81-8973 is an unmodified, full-length third generation recombinant factor VIII (rFVIII) which offers a more favorable pharmacokinetic (PK) profile, compared to its predecessor sucrose-formulated rFVIII (rFVIII-FS). We here report on a retrospective case series of nine patients affected by hemophilia A (HA), with variable disease severity, bleeding phenotype and comorbidities, to underline our clinical practice on prophylaxis with a recently introduced standard hall-life recombinant Factor VIII. The current case series highlights how the current clinical management of hemophilia is able to personalize treatment in several specific conditions like concomitant illnesses with thrombotic ris…

AdultMalemedicine.medical_specialtyAdolescentHemophilia A HemarthrosisHemophilic arthropathyrFVIIIPharmacokineticProphylaxisHaemophilia A030204 cardiovascular system & hematologyHemophilia ARecombinant factor viii03 medical and health sciencesYoung Adult0302 clinical medicinehemic and lymphatic diseasesInternal medicineMedicineHumansChildVariable disease severityAgedRetrospective StudiesThrombotic riskFactor VIIIbusiness.industryHematologyHemarthrosisMiddle Agedmedicine.diseaseThird generationClinical PracticeTreatment OutcomeConcomitantbusiness030215 immunology
researchProduct

Sensory strategies of postural sway during quiet stance in patients with haemophilic arthropathy.

2017

Introduction: The sensory strategies of postural control in adult haemophilic arthropathy patients are still poorly understood. Aim: To determine sensorial posture-control strategies through postural sway frequency analysis when in a bipedal quiet stance with and without visual stimulus deprivation in healthy subjects and patients with haemophilic arthropathy. Secondarily, to determine the irregularity of postural balance control through sample entropy (SampEn). Methods: A triaxial accelerometer attached at the L3 level determined the displacement and acceleration of the centre of mass (DCoM and ACoM, respectively) under open-and closed-eyes conditions. Sensorial strategies were studied by …

AdultMalemedicine.medical_specialtyAdolescentPosturehaemophiliaSensory systemsample entropy030204 cardiovascular system & hematologypostural controlSomatosensory systemHaemophiliaHemophilia ASeverity of Illness Indexsomatosensorycentre of mass03 medical and health sciencesYoung Adult0302 clinical medicinePhysical medicine and rehabilitationHemarthrosismedicinePostural BalanceHumansPostural BalanceGenetics (clinical)Vestibular systemHaemophilic arthropathybusiness.industryhaemophilic arthropathyHematologyGeneral Medicinemedicine.diseaseSample entropyQUIETCase-Control StudiesPhysical therapybusiness030217 neurology & neurosurgeryHaemophilia : the official journal of the World Federation of Hemophilia
researchProduct

Conversion from colonic conduit into recto-sigmoid pouch (Mainz pouch II)

2005

The Mainz Pouch II has now been used widely and found to be a valuable addition to the various types of urinary diversion. The authors from Mainz describe how a colonic conduit can be converted into a Mainz Pouch II, and the expected outcome from such a procedure. OBJECTIVE To report our long-term results of conversion from conduit conversion into a continent anal urinary diversion, as after conduit urinary diversion in childhood, some patients wish to have a later conversion to a continent diversion to avoid external appliances and to improve their quality of life. PATIENTS AND METHODS Between 1992 and 2003, 139 patients had a urinary diversion with a recto-sigmoid pouch (Mainz pouch II), …

AdultMalemedicine.medical_specialtyAdolescentUrologymedicine.medical_treatmentHyperchloraemiaUrinary DiversionPostoperative ComplicationsColon SigmoidHumansMedicineChildUreteric reimplantationRetrospective Studiesbusiness.industryUrinary Reservoirs ContinentUrinary diversionRectumUrinary Bladder DiseasesColonic conduitMean ageNephrectomySurgeryTreatment OutcomePatient SatisfactionChild PreschoolFemaleBase excessPouchbusinesshuman activitiesFollow-Up StudiesBJU International
researchProduct

Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab.

2018

Background Autoimmune thrombotic thrombocytopenic purpura (iTTP) is caused by autoantibody-mediated severe a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13 (ADAMTS13) deficiency leading to micro-angiopathic haemolytic anaemia (MAHA) and thrombocytopenia with organ damage. Patients survive with plasma exchange (PEX), fresh frozen plasma replacement and corticosteroid treatment. Anti-CD20 monoclonal antibody rituximab is increasingly used in patients resistant to conventional PEX or relapsing after an acute bout. Objective This retrospective observational study focused on the relapse rate and possible influencing factors including treatment with rituximab first…

AdultMalemedicine.medical_specialtyAdolescentautoantibodiesThrombotic thrombocytopenic purpuraADAMTS13 ProteinRelapse rate030204 cardiovascular system & hematologyGastroenterologyAutoimmune Diseases03 medical and health sciencesYoung Adult0302 clinical medicineSex FactorsRecurrenceInternal medicinehemic and lymphatic diseasesCellular Haemostasis and PlateletsMedicineHumansImmunologic Factorsclinical studiesYoung adultChildADAMS/ADAMTS13Retrospective StudiesPurpura Thrombotic Thrombocytopenicbusiness.industryRetrospective cohort studyHematologythrombotic thrombocytopenic purpura (TTP/HUS)Middle Agedmedicine.diseaseAntigens CD20ADAMTS13PurpuraTreatment Outcome030220 oncology & carcinogenesisRituximabFemaleFresh frozen plasmamedicine.symptombusinessRituximabmedicine.drugFollow-Up StudiesThrombosis and haemostasis
researchProduct

A complication risk score to evaluate clinical severity of thalassaemia syndromes

2020

The thalassaemia syndromes (TS) show different phenotype severity. Developing a reliable, practical and global tool to determine disease severity and tailor treatment would be of great value. Overall, 7910 patients were analysed with the aim of constructing a complication risk score (CoRS) to evaluate the probability of developing one or more complications. Nine independent variables were included in the investigation as predictors. Logistic regression models were used for Group A [transfusion-dependent thalassaemia (TDT)], Group B [transfused non-TDT (NTDT)] and Group C (non-transfused NTDT). Statistically significant predictors included age (years), haemoglobin levels, hepatic transaminas…

AdultMalemedicine.medical_specialtyAdolescentcomplicationsthalassaemiacomplicationrisk scoreLogistic regressionSeverity of Illness IndexGroup AGroup BHemoglobinsYoung Adult03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansprognostic modelBlood TransfusionClinical severityHemoglobinFramingham Risk ScoreEjection fractionReceiver operating characteristicbusiness.industryHematologyMiddle AgedPrognosisChelation TherapyThalassemia ...ROC Curve030220 oncology & carcinogenesisThalassemiaFemalecomplications; prognostic model; risk score; thalassaemiaComplicationbusiness030215 immunologyBritish Journal of Haematology
researchProduct